Mitochondria-penetrating peptides conjugated to desferrioxamine as chelators for mitochondrial labile iron

被引:20
作者
Alta, Roxana Y. P. [1 ,2 ]
Vitorino, Hector A. [1 ]
Goswami, Dibakar [3 ]
Liria, Cleber W. [2 ]
Wisnovsky, Simon P. [4 ]
Kelley, Shana O. [4 ,5 ]
Machini, M. Teresa [2 ]
Esposito, Breno P. [1 ]
机构
[1] Univ Sao Paulo, Inst Chem, Dept Fundamental Chem, Sao Paulo, Brazil
[2] Univ Sao Paulo, Inst Chem, Dept Biochem, Sao Paulo, Brazil
[3] Bhabha Atom Res Ctr, Bombay, Maharashtra, India
[4] Univ Toronto, Dept Biochem, Toronto, ON, Canada
[5] Univ Toronto, Fac Pharm, Toronto, ON, Canada
基金
巴西圣保罗研究基金会;
关键词
FRIEDREICHS-ATAXIA; OVERLOAD DISEASE; CELL-DEATH; DOXORUBICIN; DELIVERY; DNA;
D O I
10.1371/journal.pone.0171729
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Desferrioxamine (DFO) is a bacterial siderophore with a high affinity for iron, but low cell penetration. As part of our ongoing project focused on DFO-conjugates, we synthesized, purified, characterized and studied new mtDFOs (DFO conjugated to the Mitochondria Penetrating Peptides TAT(49-57), 1A, SS02 and SS20) using a succinic linker. These new conjugates retained their strong iron binding ability and antioxidant capacity. They were relatively non toxic to A2780 cells (IC50 40-100 mu M) and had good mitochondrial localization (Rr +0.45-+0.68) as observed when labeled with carboxy-tetramethylrhodamine (TAMRA) In general, mtDFO caused only modest levels of mitochondrial DNA (mtDNA) damage. DFO-SS02 retained the antioxidant ability of the parent peptide, shown by the inhibition of mitochondrial superoxide formation. None of the compounds displayed cell cycle arrest or enhanced apoptosis. Taken together, these results indicate that mtDFO could be promising compounds for amelioration of the disease symptoms of iron overload in mitochondria.
引用
收藏
页数:15
相关论文
共 42 条
[1]  
[Anonymous], 1997, INORGANIC BIOCH INTR
[2]   Selective iron chelation in Friedreich ataxia:: biologic and clinical implications [J].
Boddaert, Nathalie ;
Sang, Kim Hanh Le Quart ;
Roetig, Agnes ;
Leroy-Willig, Anne ;
Gallet, Serge ;
Brunelle, Francis ;
Sidi, Daniel ;
Thalabard, Jean-Christophe ;
Munnich, Arnold ;
Cabantchik, Z. Ioav .
BLOOD, 2007, 110 (01) :401-408
[3]   A fluorescence-based one-step assay for serum non transferrin-bound iron [J].
Breuer, W ;
Cabantchik, ZI .
ANALYTICAL BIOCHEMISTRY, 2001, 299 (02) :194-202
[4]   The molecular and cellular basis of iron toxicity in Iron Overload (IO) disorders. Diagnostic and therapeutic approaches [J].
Cabantchik, Zvi Ioav ;
Sohn, Yan Sung ;
Breuer, William ;
Esposito, Breno Pannia .
THALASSEMIA REPORTS, 2013, 3 :7-13
[5]   Targeted Delivery of Doxorubicin to Mitochondria [J].
Chamberlain, Graham R. ;
Tulumello, David V. ;
Kelley, Shana O. .
ACS CHEMICAL BIOLOGY, 2013, 8 (07) :1389-1395
[6]   Targeting proteins to mitochondria using TAT [J].
Del Gaizo, V ;
MacKenzie, JA ;
Payne, RM .
MOLECULAR GENETICS AND METABOLISM, 2003, 80 (1-2) :170-180
[7]   Endosomal and lysosomal effects of desferrioxamine: Protection of HeLa cells from hydrogen peroxide-induced DNA damage and induction of cell-cycle arrest [J].
Doulias, PT ;
Christoforidis, S ;
Brunk, UT ;
Galaris, D .
FREE RADICAL BIOLOGY AND MEDICINE, 2003, 35 (07) :719-728
[8]   Iron chelation in the treatment of neurodegenerative diseases [J].
Dusek, Petr ;
Schneider, Susanne A. ;
Aaseth, Jan .
JOURNAL OF TRACE ELEMENTS IN MEDICINE AND BIOLOGY, 2016, 38 :81-92
[9]   Labile plasma iron in iron overload: redox activity and susceptibility to chelation [J].
Esposito, BP ;
Breuer, W ;
Sirankapracha, P ;
Pootrakul, P ;
Hershko, C ;
Cabantchik, ZI .
BLOOD, 2003, 102 (07) :2670-2677
[10]   A review of fluorescence methods for assessing labile iron in cells and biological fluids [J].
Espósito, BP ;
Epsztejn, S ;
Breuer, W ;
Cabantchik, ZI .
ANALYTICAL BIOCHEMISTRY, 2002, 304 (01) :1-18